Xaira Therapeutics, a company harnessing AI for drug discovery and development, revealed its launch backed by over $1 billion in capital.

Investors in biotech are placing significant bets on the potential for computational methods to revolutionize drug discovery.

The biotech firm is a collaborative effort between ARCH Venture Partners and Foresite Labs, the primary investors in the funding round.

Xaira utilizes machine learning and data models for AI-driven drug discovery.

Xaira’s CEO Marc Tessier-Lavigne, a former Stanford president and chief scientific officer at Genentech says

the company's advancements in artificial intelligence have opened doors to develop drugs never before possible.

For interesting and latest updates  CLICK BELOW